FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology. Disclosed is an oligonucleotide to allow skipping of two or more exons of dystrophin pre-mRNA. Also disclosed is a composition to enable skipping of two or more exons of dystrophin pre-mRNA, a method and use of the oligonucleotide and composition for preventing, slowing down, alleviating and / or treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
EFFECT: present invention may find further application in the treatment of various diseases caused by mutations in the dystrophin gene.
5 cl, 5 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number | 
|---|---|---|---|
| OLIGONUCLEOTIDE FOR TREATMENT OF PATIENTS WITH MUSCULAR DYSTROPHY | 2013 | 
 | RU2789279C2 | 
| SYSTEM OF TARGETED SPLICING CHANGES IN MARK2 GENE | 2023 | 
 | RU2810907C1 | 
| ANTISENSE NUCLEIC ACIDS | 2011 | 
 | RU2567664C2 | 
| DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 | 
 | RU2820247C2 | 
| ANTISENSE NUCLEIC ACIDS | 2012 | 
 | RU2619184C2 | 
| ANTISENSE NUCLEIC ACIDS | 2018 | 
 | RU2681470C1 | 
| ANTISENSE NUCLEIC ACIDS | 2012 | 
 | RU2651468C1 | 
| ANTISENSE NUCLEIC ACIDS | 2015 | 
 | RU2702424C2 | 
| ANTISENSE NUCLEIC ACIDS | 2015 | 
 | RU2730681C2 | 
| NEW METHOD OF TREATING RETINITIS PIGMENTOSA | 2020 | 
 | RU2817702C2 | 
Authors
Dates
2018-12-11—Published
2013-07-03—Filed